|
Complete atrioventricular block
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Thus, minimally invasive TBX18 gene transfer creates physiologically relevant pacemaker activity in complete heart block, providing evidence for therapeutic somatic reprogramming in a clinically relevant disease model.
|
25031269 |
2014 |
|
Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our analyses also suggest a role in atherosclerosis for developmental transcription factor genes having little or no previous association with atherosclerosis, such as NR2F2 (COUP-TFII) and TBX18.
|
30529831 |
2019 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our analyses also suggest a role in atherosclerosis for developmental transcription factor genes having little or no previous association with atherosclerosis, such as NR2F2 (COUP-TFII) and TBX18.
|
30529831 |
2019 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Analysis of tumor suppressor properties of two aberrantly methylated transcription factors, HOXB13 and TBX18, revealed that both inhibited growth and clonogenic survival of colon cancer cells in vitro, but only HOXB13 abolished tumor growth in nude mice.
|
20454457 |
2010 |
|
Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry validated the discriminative value of corresponding endothelial protein expression between early (fractalkine/CX3CL1, IP10/CCL10, TBX18) or advanced (BAX, NFKB2) stages of atherosclerosis and versus their plaque-free controls.
|
17591977 |
2007 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry validated the discriminative value of corresponding endothelial protein expression between early (fractalkine/CX3CL1, IP10/CCL10, TBX18) or advanced (BAX, NFKB2) stages of atherosclerosis and versus their plaque-free controls.
|
17591977 |
2007 |
|
Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Three intragenic Tbx18 polymorphisms were used to map the region of maximum AI to within the gene itself; 16 of 17 tumours exhibited imbalances of at least one of these markers.
|
12663494 |
2003 |
|
Ventricular Fibrillation
|
0.010 |
Biomarker
|
disease |
BEFREE |
The duration of ventricular fibrillation (VF) was higher in the lentiviral Tbx18 group compared with the GFP-injected controls (P = 0.02) and the Tbx18-pacemaker cell group (P = 0.02).
|
30677516 |
2019 |
|
Rhythm from artificial pacing
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Following a previous in vitro study reporting the production of Tbx18-expressing human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs), we aimed to investigate the efficacy of these engineered cells to generate pacemaker rhythms in a murine model of complete heart block.
|
30677516 |
2019 |
|
Pacing-induced cardiomyopathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
In protocol B, full-blown RV PICM was evident 4 weeks after complete AV block in both groups; subsequent intervention led to higher mean heart rate (56 ± 2 beats/min vs. 50.1 ± 0.4 beats/min; p = 0.05), less backup pacemaker utilization (53 ± 8.2% vs. 95 ± 1.6%; p = 0.003), and a greater ejection fraction (61.7 ± 1.3% vs. 49 ± 1.6%; p = 0.0003) in TBX18-injected animals versus control animals.
|
30947921 |
2019 |
|
Congenital Heart Defects
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Congenital heart defects could be linked to deletions of MAP3K7 (6q15) or TBX18 (6q14.3).
|
29904178 |
2018 |
|
Kidney Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The TBX18 transcription factor is a crucial developmental regulator of several organ systems in mice, and loss of its transcriptional repression activity causes dilative nephropathies in humans.
|
30071041 |
2018 |
|
Sick Sinus Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Gene therapy targeting TBX18 could therefore have the potential to restore pacemaker function in human sick sinus syndrome obviating electronic pacemakers.
|
30259525 |
2018 |
|
Coronary heart disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We speculated that the DNA sequence variants (DSVs) within TBX18 gene promoter may mediate CHD development by affecting TBX18 levels and the cardiac gene regulatory network.
|
23749171 |
2013 |
|
Ventricular Septal Defects
|
0.010 |
GeneticVariation
|
group |
BEFREE |
In this study, we genetically and functionally analyzed the TBX18 gene promoter in patients with ventricular septal defects (VSD) (n = 326) and ethnic-matched healthy controls (n = 327).
|
23749171 |
2013 |
|
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Allelic imbalance at intragenic markers of Tbx18 is a hallmark of murine osteosarcoma.
|
12663494 |
2003 |
|
Osteosarcoma of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
Allelic imbalance at intragenic markers of Tbx18 is a hallmark of murine osteosarcoma.
|
12663494 |
2003 |
|
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Allelic imbalance at intragenic markers of Tbx18 is a hallmark of murine osteosarcoma.
|
12663494 |
2003 |